-Vertex Pharmaceuticals Incorporated and Zai Lab Limited announced an exclusive collaboration and license agreement for the development a...
Andreessen Horowitz (a16z) Bio + Health announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health...
-Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma announced a strategic partnership to accelerate the development and commercializatio...
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) announce...
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-c...
etherna immunotherapies NV (“etherna”), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announc...
InkSpace Imaging, a leader in MRI coil innovation, announced that the United States (US) Food and Drug Administration (FDA) has cleared InkSpace Imaging&rs...
HUTCHMED (China) announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISSO&re...
Corcept Therapeutics, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metab...
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancer...
Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Ma...
Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Cha...
the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like pep...
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), announced that the first patient has been dosed in the pivotal Phase 3 Aspire study (NCT06617429) ...
© 2025 Biopharma Boardroom. All Rights Reserved.
